Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up-A Copenhagen Experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Lymphopenia and neutropenia are associated with subsequent incident proteinuria in Danish patients with systemic lupus erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Febrile neutropenia (FN) after chemotherapy causes a high burden of morbidity and mortality. We aimed to develop and validate a risk score to predict FN in the first cycle of chemotherapy.

Methods: We included patients with solid cancers and diffuse large B-cell lymphomas at Rigshospitalet, University of Copenhagen, 2010-2016. Predictors of FN were analyzed using Poisson regression and random split-sampling.

Results: Among 6294 patients in the derivation cohort, 360 developed FN. Female sex, older age, cancer type, disease stage, low albumin, elevated bilirubin, low creatinine clearance, infection before chemotherapy, and number of and type of chemotherapy drugs predicted FN. Compared with those at low risk (n = 2520, 40.0%), the incidence rate ratio of developing FN was 4.8 (95% confidence interval [CI] = 2.9 to 8.1), 8.7 (95% CI = 5.3 to 14.1) and 24.0 (95% CI = 15.2 to 38.0) in the intermediate (n = 1294, 20.6%), high (n = 1249, 19.8%) and very high (n = 1231, 19.6%) risk groups, respectively, corresponding to a number needed to treat with granulocyte colony-stimulating factors to avoid one FN event in the first cycle of 284, 60, 34 and 14. The discriminatory ability (Harrell's C-statistic = 0.80, 95% CI = 0.78 to 0.82) was similar in the validation cohort (n = 3163) (0.79, 95% CI = 0.75 to 0.82).

Conclusion: We developed and internally validated a risk score for FN in the first cycle of chemotherapy. The FENCE score is available online and provides good differentiation of risk groups.

Original languageEnglish
JournalJNCI cancer spectrum.
Volume2
Issue number4
Pages (from-to)pky053
ISSN2515-5091
DOIs
Publication statusPublished - Oct 2018

ID: 59182435